← All trials
NCT04319718
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2020
- Primary completion
- May 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Mar 24, 2020
- Last posted
- Apr 15, 2020
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of PittsburghLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of PittsburghReponsible party - principal investigator
- University of PittsburghOverall official - principal investigator
- University of PittsburghStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.